Acalnib Acalabrutinib 100 mg Capsules

Acalabrutinib 100 mg Capsules, marketed under the brand name Acalnib, is a prescription-only oral oncology medicine containing the active ingredient Acalabrutinib. It belongs to the class of targeted cancer therapies known as Bruton’s Tyrosine Kinase (BTK) inhibitors. This product is manufactured for regulated pharmaceutical supply chains and is offered strictly for international export to licensed distributors, hospitals, and oncology treatment centers. AmeriDrugs does not supply this product for retail or direct patient purchase.

Active Ingredient

• Acalabrutinib – 100 mg per capsule
  Acalabrutinib is a selective BTK inhibitor developed for use within approved oncology treatment frameworks under medical supervision.

Therapeutic Use
From an informational and regulatory perspective, Acalabrutinib is used in approved oncology indications involving specific hematological malignancies, as defined by regulatory authorities in the importing country. This information is provided solely for product identification and international trade reference. AmeriDrugs does not provide medical advice, treatment recommendations, or patient-level guidance.

Dosage Form

• Oral solid dosage form
• Hard gelatin capsules
• Supplied in unit-dose packaging suitable for institutional and hospital pharmacy use
• Administration and treatment protocols are determined exclusively by qualified oncology professionals in accordance with local regulations

Quality & Manufacturing Standards
Acalabrutinib 100 mg Capsules (Acalnib) are manufactured in facilities operating under GMP-compliant quality systems. Production follows validated pharmaceutical processes, including raw material qualification, in-process controls, and finished product testing to ensure identity, strength, purity, and consistency in line with international export standards.

Packaging Information

• Pack size: 30 capsules per box
• Pharmaceutical-grade blister or bottle packaging (as applicable)
• Secure secondary packaging designed for export handling and international logistics
• Labeling aligned with regulated oncology supply requirements

Target Buyers
This product is intended exclusively for supply to:

• Licensed pharmaceutical importers and distributors
• Hospitals and oncology treatment centers
• Government and private cancer care institutions
• Authorized healthcare procurement agencies

It is not intended for retail pharmacies, online consumer sales, or direct patient distribution.

Regulatory & Compliance Note
Acalabrutinib 100 mg Capsules (Acalnib) is a prescription-only oncology medicine. Importation, distribution, and use must comply with the pharmaceutical laws, drug authority approvals, and oncology regulations of the destination country. Buyers are responsible for ensuring regulatory compliance within their jurisdiction. AmeriDrugs operates solely as an export-focused pharmaceutical supplier and does not promote this product for self-medication or non-regulated use.